These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19911974)

  • 1. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.
    Jenks N; Myers R; Greiner SM; Thompson J; Mader EK; Greenslade A; Griesmann GE; Federspiel MJ; Rakela J; Borad MJ; Vile RG; Barber GN; Meier TR; Blanco MC; Carlson SK; Russell SJ; Peng KW
    Hum Gene Ther; 2010 Apr; 21(4):451-62. PubMed ID: 19911974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
    Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
    J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats.
    Ebert O; Shinozaki K; Huang TG; Savontaus MJ; García-Sastre A; Woo SL
    Cancer Res; 2003 Jul; 63(13):3605-11. PubMed ID: 12839948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.
    Shinozaki K; Ebert O; Kournioti C; Tai YS; Woo SL
    Mol Ther; 2004 Mar; 9(3):368-76. PubMed ID: 15006603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
    Obuchi M; Fernandez M; Barber GN
    J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer.
    Ebert O; Shinozaki K; Kournioti C; Park MS; García-Sastre A; Woo SL
    Cancer Res; 2004 May; 64(9):3265-70. PubMed ID: 15126368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
    Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
    Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.
    Myers R; Harvey M; Kaufmann TJ; Greiner SM; Krempski JW; Raffel C; Shelton SE; Soeffker D; Zollman P; Federspiel MJ; Blanco M; Galanis E
    Hum Gene Ther; 2008 Jul; 19(7):690-8. PubMed ID: 18576918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
    Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo.
    Altomonte J; Wu L; Chen L; Meseck M; Ebert O; García-Sastre A; Fallon J; Woo SL
    Mol Ther; 2008 Jan; 16(1):146-53. PubMed ID: 18071337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.
    Shinozaki K; Ebert O; Woo SL
    Hepatology; 2005 Jan; 41(1):196-203. PubMed ID: 15619242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
    Smith KER; Peng KW; Pulido JS; Weisbrod AJ; Strand CA; Allred JB; Newsom AN; Zhang L; Packiriswamy N; Kottke T; Tonne JM; Moore M; Montane HN; Kottschade LA; McWilliams RR; Dudek AZ; Yan Y; Dimou A; Markovic SN; Federspiel MJ; Vile RG; Dronca RS; Block MS
    Front Immunol; 2023; 14():1279387. PubMed ID: 38022659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
    Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
    Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
    Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
    Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice.
    Tesfay MZ; Kirk AC; Hadac EM; Griesmann GE; Federspiel MJ; Barber GN; Henry SM; Peng KW; Russell SJ
    J Virol; 2013 Apr; 87(7):3752-9. PubMed ID: 23325695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.